Asset profile
Solengepras (CVN424)
Small molecule
Evidence outlook · registrational
Parkinson's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT04191577: Randomized, quadruple-masked, placebo-controlled phase 2 in Parkinson's disease with motor fluctuations (136 participants). The registered primary outcome is the rate of drug-related adverse events, reported descriptively without a statistical comparison; efficacy measures were secondary.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.